Who Owns Edgewise Therapeutics Company?

Edgewise Therapeutics Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Controls Edgewise Therapeutics?

In the fast-paced world of biotech, knowing who owns a company is critical for understanding its future. Edgewise Therapeutics, a clinical-stage biopharmaceutical firm, is making waves with its focus on severe muscle disorders. But who are the key players shaping the destiny of Edgewise Therapeutics SWOT Analysis and its innovative treatments?

Understanding the dynamics of Edgewise ownership is essential for anyone tracking the company. From its early backers to its current Edgewise investors, the shifts in ownership provide valuable insights. This analysis will explore the evolution of Edgewise stock and its stakeholders, offering a comprehensive view of the company's trajectory, including details about Edgewise executives and Edgewise management.

The formation of Edgewise Therapeutics in 2017 marked the beginning of its journey in the biopharmaceutical sector. The company's early structure and ownership were shaped by its founding team and initial investors. Understanding the founders and early investors provides insights into the company's strategic direction and financial backing.

Alan Russell, Ph.D., Peter Thompson, M.D., and Badreddin Edris, Ph.D., co-founded Edgewise Therapeutics. Their combined expertise in science, medicine, and business laid the groundwork for the company's focus on developing treatments for muscle disorders. Peter Thompson's role as a Partner at OrbiMed and Badreddin Edris's position as Chief Operating Officer of SpringWorks Therapeutics highlight the founders' industry connections.

Alan Russell currently serves as the Co-Founder, Chief Scientific Officer, and a Director of the company. The early ownership structure was significantly influenced by the initial funding rounds, which attracted prominent investors in the life sciences field. These investments were crucial for advancing Edgewise's lead product candidate into clinical development.

Founding Team

The founders of Edgewise Therapeutics are Alan Russell, Peter Thompson, and Badreddin Edris. Their diverse backgrounds contributed to the company's initial strategy. The founders' industry connections played a key role in securing early investments.

Early Funding

Edgewise Therapeutics secured a $50 million Series B financing round in September 2019. This round was co-led by Novo Holdings A/S and U.S. Venture Partners (USVP). Existing investor OrbiMed Advisors, Deerfield Management, and New Leaf Venture Partners also participated.

Series C Financing

In December 2020, Edgewise Therapeutics closed a $95 million Series C preferred stock financing. Viking Global Investors led this round. New investors included Janus Henderson Investors, Surveyor Capital, and RA Capital Management.

Investor Participation

Existing investors from the Series B round also participated in the Series C offering. This included OrbiMed, Novo Holdings, USVP, Deerfield Management, New Leaf Ventures, and CureDuchenne Ventures. This demonstrated continued confidence in the company's potential.

Use of Funds

The Series C funding was earmarked to advance the clinical development of EDG-5506. The focus was on treating Becker and Duchenne muscular dystrophy and other rare muscle diseases. This reflected the founders' vision for addressing unmet medical needs.

Key Executives

Alan Russell serves as Co-Founder, Chief Scientific Officer, and a Director. Peter Thompson is a Partner at OrbiMed. Badreddin Edris is the Chief Operating Officer of SpringWorks Therapeutics.

Ownership & Investment Details

The early ownership of Edgewise Therapeutics was shaped by the founders and the investors who participated in the Series B and C financing rounds. The initial investments provided the necessary capital to support the company's research and development efforts. Understanding the early ownership structure helps to clarify the company's strategic direction and financial backing. For more details on the competitive landscape, you can review the Competitors Landscape of Edgewise Therapeutics.

• The Series B round in September 2019 raised $50 million, with participation from Novo Holdings A/S, U.S. Venture Partners (USVP), OrbiMed Advisors, Deerfield Management, and New Leaf Venture Partners.
• The Series C round in December 2020 raised $95 million, led by Viking Global Investors, with participation from Janus Henderson Investors, Surveyor Capital, RA Capital Management, Cormorant Asset Management, Logos Capital, and Wellington Management.
• These investments were crucial in supporting the advancement of Edgewise's lead product candidate into clinical development, particularly for Becker and Duchenne muscular dystrophy.
• The participation of existing investors in the Series C round demonstrated continued confidence in the company's potential and strategy.

Edgewise Therapeutics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The journey of Edgewise Therapeutics from a private entity to a publicly traded company is a pivotal aspect of its ownership evolution. The company's Initial Public Offering (IPO) on March 26, 2021, marked a significant shift, with the company listing on Nasdaq under the ticker symbol EWTX. The IPO, priced at $16 per share, successfully raised $176 million. This transition not only provided capital but also opened the door for a broader investor base, fundamentally altering the Edgewise ownership landscape.

Since its IPO, Edgewise Therapeutics has experienced substantial growth, reflected in its market capitalization. Initially valued at $761.07 million at the IPO, the company's market cap reached $1.66 billion as of June 11, 2025. This represents a significant increase of 117.71%, demonstrating the company's expansion and the growing confidence of investors. This growth is a key indicator of the company's success and its ability to attract and retain investment.

As of April 2025, institutional investors hold a significant portion of Edgewise Therapeutics' shares. With 412 institutional owners and shareholders, the total holdings amount to 115,199,677 shares. Key institutional players include OrbiMed Advisors LLC, which, as a co-founder, retains a substantial stake of 14.5% of the shares, totaling 15,252,867 shares. The involvement of firms like RA Capital Management, L.P., and Perceptive Advisors LLC further highlights the confidence in the company's potential. For more insights into the company's journey, explore the Brief History of Edgewise Therapeutics.

Ownership Insights

Edgewise Therapeutics' ownership structure has evolved significantly since its IPO, with institutional investors playing a crucial role.

• OrbiMed Advisors LLC, a co-founder, remains a major shareholder.
• Institutional investors hold a substantial number of shares, demonstrating confidence.
• The company's market cap has increased significantly since the IPO.
• Peter A. Thompson, a director at OrbiMed, increased his stake in the company.

Edgewise Therapeutics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors of Edgewise Therapeutics includes a mix of individuals representing major shareholders, founders, and independent members. This structure aims to blend strategic oversight with industry expertise. Key figures include Kevin Koch, Ph.D., who serves as President, Chief Executive Officer, and a Director. Co-founders Alan J. Russell, Ph.D., and Badreddin Edris, Ph.D., also hold positions on the board. Peter Thompson, M.D., a co-founder and Partner at OrbiMed, represents a significant institutional investor and is also a board member. This composition highlights the influence of both founders and major investors on the company's governance.

Other board members include Laura Brege, a Senior Advisor at BridgeBio Pharma, and Jonathan C. Fox, M.D., Ph.D., FACC, who is the president and chief medical officer for cardiovascular and renal diseases at BridgeBio Pharma. These members bring substantial experience from the biotechnology and pharmaceutical sectors to the board. The presence of these individuals underscores the company's focus on leveraging industry expertise for strategic decision-making and operational guidance. The board's composition reflects a balance between internal leadership, significant shareholder representation, and external industry knowledge.

The influence of major shareholders is evident through board representation and insider transactions. For instance, Peter A. Thompson and OrbiMed Advisors LLC's recent share acquisitions in April 2025 demonstrate the direct involvement of significant shareholders in the company's ownership and governance. While specific details regarding dual-class shares or special voting rights are not explicitly detailed in publicly available information, the presence of institutional investors like OrbiMed Advisors LLC, with its substantial holdings and board representation, indicates a strong influence over strategic decisions. For more detailed information on the company's financial model, you can refer to Revenue Streams & Business Model of Edgewise Therapeutics.

Key Takeaways on Edgewise Ownership

The board of directors at Edgewise Therapeutics is composed of a mix of founders, major shareholders, and independent members. This structure is designed to balance strategic oversight with industry expertise.

• Kevin Koch, Ph.D., serves as President, CEO, and Director.
• Peter Thompson, M.D., represents OrbiMed, a significant institutional investor.
• Insider transactions, such as share acquisitions in April 2025, show direct shareholder involvement.
• The company's SEC filings provide detailed insights into voting power and ownership distribution.

Edgewise Therapeutics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, the ownership landscape of Edgewise Therapeutics has seen significant shifts. The company's initial public offering (IPO) in March 2021 marked a pivotal moment, broadening its shareholder base and significantly increasing its market capitalization. As of June 11, 2025, the market cap of Edgewise Therapeutics is approximately $1.66 billion. This growth reflects the company's evolving position in the market and its ability to attract investors.

Recent financial activities and strategic decisions have also influenced the ownership structure. On April 2, 2025, Edgewise Therapeutics announced a $200 million underwritten public offering of common stock. Existing major shareholders, such as OrbiMed Advisors LLC, participated in this offering, acquiring 496,771 shares for about $10 million on April 3, 2025. This demonstrates continued confidence from key investors, even amid stock fluctuations. These actions highlight the ongoing interest in Edgewise stock and the company's efforts to secure funding for future operations, with the offering expected to support activities through 2028.

The biotechnology sector is seeing increased institutional ownership, and Edgewise Therapeutics is no exception. As of April 2025, institutional investors held over 115 million shares. Despite some insider sales in 2024, recent acquisitions by OrbiMed and Peter Thompson in April 2025 signal strong commitment from significant shareholders. Furthermore, the company’s robust liquidity, with a current ratio of 19.93 as of April 2025, positions it well for strategic moves. For more insights, consider reading about the Target Market of Edgewise Therapeutics.

Edgewise Ownership Overview

The IPO in March 2021 broadened Edgewise Therapeutics' ownership base. As of June 11, 2025, the market cap is around $1.66 billion. Recent stock offerings and acquisitions show continued investor interest in Edgewise stock.

Key Investors

OrbiMed Advisors LLC acquired approximately $10 million in shares in April 2025. Institutional investors collectively hold over 115 million shares. These investments demonstrate confidence in the company's prospects.

Financial and Strategic Moves

A $200 million public offering was announced on April 2, 2025. The offering is expected to fund operations through 2028. The company's strong liquidity is a positive indicator.

Leadership Changes

Robert Blaustein, M.D., Ph.D., joined as Chief Development Officer in January 2025. Behrad Derakhshan, Ph.D., was promoted to Chief Operating Officer in January 2025. These changes aim to strengthen the company's focus on late-stage clinical development and prepare for potential commercialization.

Edgewise Therapeutics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs